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Introduction
Vaccination against cancer has a long history of trial and error with only a few encouraging results. [1] [2] [3] [4] Tumors, in contrast to infectious agents, develop over long time spans with no associated inflammatory responses and may thus be capable of inducing T cell tolerance. 5 A number of tumor-associated antigens (TAA) have now been described and our knowledge of how these antigens are presented to the immune system has increased. 6, 7 The present challenge is to reintroduce tumor antigens into the immune system in such a way that efficient antitumor responses are induced, in a therapeutic setting. The most widely used vaccines in clinical studies are whole tumor cells either alone or in combination with B7 or cytokine genes. [8] [9] [10] More recent approaches include vaccination with peptide, recombinant viral and bacterial nucleic acid, heat-shock proteins or dendritic cells (DC). 1, 2 However, there is presently no consensus on which of these different vaccine types are optimal for tumor immunotherapy.
TAAs include tumor-specific shared antigens, differentiation antigens, mutated proteins, antigens derived from oncogenes and viral antigens. 11 The mouse P815 mastocytoma represents a model for the first type of tumor antigens, expressing a weak transplantation antigen (P815A), encoded by the gene P1A, containing an immunodominant Ld restricted epitope. [12] [13] [14] The P815 antigen shares many characteristics found in some identified human TAA genes, such as those belonging to the MAGE family in melanomas and other tumors. 15, 16 These antigens are not expressed in most adult tissues, with the exception of testis and placenta. However, the expression of P1A and MAGE genes in these tissues may have no major consequences in terms of cellular immunotherapy, since spermatogonia and trophoblasts do not express MHC class I. 17 Earlier studies performed by Warnier and colleagues 18 with the P815 system showed that a recombinant adenovirus-based vaccine could induce a specific CTL response. Moreover, Rosato and collaborators 19 using a DNA-CMV-based plasmid encoding the P1A gene, showed both CTL induction and some protection from a P815 tumor challenge in vaccinated mice.
Alphavirus vectors, including Semliki Forest virus (SFV), Sindbis virus and Venezuelan equine encephalitis virus (VEE), have been tested in several vaccination studies. [20] [21] [22] [23] [24] They have many attractive properties such as a high level of recombinant protein production, a transient expression (non-replicative) and a broad host range. In the SFV system foreign genes are cloned into an expression vector and by cotransfection of packaging cells with a helper virus construct, recombinant SFV viral particles are produced. 25 These particles have been demonstrated to be strictly suicidal, 26 excluding the risk of wild-type SFV spreading as a result of RNA recombination during in vivo rSFV packaging.
In the present work, we have used recombinant SFV as a vaccine for expression of the P815A antigen. The SFV system was chosen since it was earlier shown to generate strong CTL and antibody responses and to protect against challenge with Influenza virus. 23, 24, [27] [28] [29] Our results demonstrate that vaccination of mice with recombinant SFV expressing the P815A antigen induces strong and specific CTL responses and protect mice against tumor growth. We conclude that recombinant SFV is a promising vector system which might be further optimized in order to activate immune responses against cancer.
Results
Expression of P1A by recombinant SFV To check the expression of P1A by recombinant SFV vectors (Figure 1 ), BHK cells were infected and protein expression analyzed by 35 S-methionine labeling ( Figure  2a ). Total cell lysates showed a high level of P1A expression. SFV-P1A produced a protein with an apparent size of 40 kDa. The Enh-P1A is a fusion protein where 34 amino acids residues of the capsid protein of SFV preceed the P1A polypeptide. Indeed, the product was slightly larger than native P1A. The translational enhancing activity was reflected in the fact that Enh-P1A was produced in larger amounts. The identity of the bands was confirmed by immunoprecipitation with specific antibodies (Figure 2b ).
Immune responses against P815 DBA/2 mice were immunized with 10 6 IU of recombinant SFV by i.v. injection. The cytotoxic activity was evaluated against P815 cells or against the H-2 d cell line L1210 pulsed with P815A [35] [36] [37] [38] [39] [40] [41] [42] [43] peptide. As shown in Figure 3a , a strong CTL response was observed when mice were immunized with the SFV constructs carrying P1A. Immunization with different amounts of SFV/Enh-P1A showed that 10 6 IU generated a strong specific lysis of P815 target cells, and already 10 2 -10 3 IU were enough to generate high levels of CTL lysis (Figure 3b) . No difference in CTL activity was observed by inclusion of the translation enhancer in front of the P1A gene. Injection of mice with SFV expressing an irrelevant antigen such as ␤-galactosidase (SFV-LacZ) failed to elicit a CTL response against P815.
Immunization of DBA male mice with rSFV carrying the P1A gene did not generate autoimmune lesions in testis. Careful histopathological examination of paraffin tissue sections did not reveal any inflammatory or lymphocytic infiltrates (data not shown). This result is in agreement with earlier observations by Uyttenhove and colleagues. 17 We were not able to detect any anti-P815 IgG in sera from mice immunized with rSFV-P1A by ELISA, in contrast with the high antibody titers found in SFV-NP and SFV-LacZ vaccinated mice 22, 24 (data not shown). 
S)-Met and total cell lysates run on SDS-PAGE. SFVLacZ infected cell-lysate shows a 46 kDa band probably reflecting incomplete shut off of host cell protein synthesis, which normally occurs during alphavirus replication. (b) Proteins indicated by arrows were confirmed by immunoprecipitation with specific antibodies.
Protection against P815 tumor challenge To evaluate whether vaccination with rSFV would protect mice against a lethal challenge with P815 tumor cells, DBA/2 mice were injected twice i.v. with 10 6 IU of SFV-P1A or SFV/Enh-P1A. Untreated mice or mice immunized with SFV expressing influenza NP (SFV-NP) served as negative and vector controls, respectively. Eighteen days after boosting, mice were challenged by subcutaneous injection of 10 5 P815 tumor cells. The appearance of tumors was recorded over a 100-day period (Figure 4) . While 80-90% of the control mice rapidly developed tumors, 90% of the SFV/Enh-P1A, and 70% of the SFV-P1A vaccinated mice did not. All tumor bearing mice died over a period of 30 days after tumor appearance. Anti-P815 CTLs were detected even 100 days after immunization (data not shown), suggesting that CTL memory was established.
Discussion
In this study we examined the capacity of rSFV to function as a vaccine in a tumor model. Immunization of mice with rSFV expressing P1A generated a strong anti-P815 specific CTL response. The same vaccine constructions significantly protected mice from a challenge with P815 tumor cells, compared with SFV-NP immunized or unvaccinated mice. No adverse effects were seen on testicular cells, which are also known to express the P815 antigen.
The CTL response to P815 tumor cells is generated against five different epitopes, designated A-E. 30 The P1A gene encodes for an antigen comprising the A and B epitopes. 14 Earlier studies demonstrated that a CTL-dependent P815 tumor rejection depends on T helper cells 31, 32 and requires production of endogenous ␥-IFN and IL-12 33 which can be induced by vaccination with inactivated whole cell preparations. 34 It has been previously shown that the generation of protective CTL responses depends on the mode of P815 tumor injection. As few as 600 tumor cells injected i.p. consistently leads to tumor growth, whereas subcutaneous injection in the footpad with 10 6 cells leads to progressive tumors in 30-40% of the mice. 35 In the present study, we injected P815 tumor cells s.c. in the flank. Tumors grew progressively in 85% of the mice, providing us with a suitable challenge system.
The precursor frequency of anti-P815 CTLs is low, as demonstrated by different responses (A-E) in individual lymph nodes after tumor challenge. 30 Thus, the CTL response in the present system could be limited by several factors regulating a functional interface between pro- fessional APCs and responding T cells. This weak P815 CTL response may also be reflected in the somewhat faster tumor development in the rSFV-NP immunized control mice compared with unvaccinated mice (Figure 4 ). In these animals, the expression of the recombinant NP antigen may be diverting the weak transplantation response against the P815 tumor challenge possibly by 'antigenic competition'. 36 This threshold character of the P815 CTL response might also explain the slightly better protective effect with the rSFV-P1A construct that contained an enhancer sequence.
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A number of options are available to optimize CTL responses against P815. One would be to inject rSFV-P1A at multiple sites, allowing pCTLs in many different lymph nodes to respond. Another, to include in the construct cytokine genes which are known to favor Th1 responses and CTL activation, in particular IL-12. 37, 38 In the present system it is unclear which host cells primarily express the recombinant antigen after i.v. or s.c. injection of rSFV-P1A. Wild-type SFV infects a broad range of host cells by endosomal uptake. In a preliminary study we have found ␤-gal expression, after i.v. injection of rSFV-LacZ, in different spleen compartments, including the white and the red pulp as well as endothelial vascular cells (Colmenero et al, unpublished data) . As the SFV infection is lytic and the infected host cells die by an apoptotic mechanism, 39 it is unclear if the infected cells can act as APC or if the CTL response is generated by uptake of apoptotic bodies into professional APCs, ie by cross-priming. 40 What is clear, however, is that the expressed P815 antigen must be handled very efficiently since doses as low as 100 IU could generate a significant CTL response, as previously also reported for rSFV-NP. 22 100 IU, by definition, can infect a maximum of 100 host cells and, as rSFV is non-replicative, the amount of P815 antigen expressed in these 100 cells must be enough to generate a CTL response. This supports a cross-priming event, in which material from a few rSFV infected cells could be taken up and processed by a larger number of APCs. 40 Mice immunized with rSFV-P1A failed to develop an antibody response to the P815 antigen, in contrast to the strong anti-NP response to rSFV-NP (data not shown). This could either depend on the subcellular localization of the antigen, as demonstrated in other systems, 41, 42 or on a pre-existing self-tolerance against P1A, both at the B and helper T cell levels. In the P815 system, the lack of an antibody response against P815 is less important as it is the CTL response that protects against tumor growth. However, if an antibody response would be desirable, it could probably be achieved by either expressing a secreted form of P1A or including co-linear helper epitopes in the recombinant protein. 43, 44 The use of viral vector systems has certain advantages over other vaccination approaches. Peptide-based vaccines encoding for T cell epitopes have been tested in several studies and sometimes found to lead to immunological tolerance due to peptide loading of class I molecules on to non-professional APCs. 45, 46 In addition, a peptide vaccine is limited to the range of the population that carry the corresponding MHC restriction element. Genetically modified whole cell tumor vaccines (such as cytokine-gene transduced autologous cells), [8] [9] [10] have the disadvantage of introducing a lot of potential irrelevant antigenic material which might cause unspecific and adverse effects, together with the complication of requiring large numbers of individual tumor cells.
Several other viral vectors, such as pox viruses and adenovirus, are currently being used for vaccination. 47 Employment of these viral vectors in humans has the potential problem of a pre-existing immunity interfering with vaccine take. 48 In fact, strong immune responses against vaccinia vector components have been observed. [49] [50] [51] In contrast, as SFV is not widespread, the risk of pre-existing immunity against this vector is minimal. In fact, previous studies showed that even when mice were multiply exposed to rSFV, they were not hampered in their ability to mount an immune response to a subsequent rSFV vaccine. 24 Finally, as the SFV-RNA replicates in the cytoplasm resulting in the death of the infected host cell, there is no risk of chromosomal integration.
In summary, we have shown that use of rSFV can induce protective immunity against tumor challenge, suggesting that it constitutes an efficient system for vaccination and antigen presentation.
Materials and methods
Cell lines P815 mastocytoma and L1210 leukemia cell lines derived from DBA/2 mice (H-2D) (kindly provided by Dr Aline Van Pel, Ludwig Institute for Cancer Research, Brussels, Belgium), were grown in RPMI-1640 medium supplemented with 10% FCS, 2 mm glutamine and antibiotics (streptomycin 100 g/ml and penicillin 100 IU/ml). BHK-21 (baby hamster kidney) were grown in BHK medium supplemented with 5% FCS, 10% tryptose phosphate broth, 2 mm glutamine, 20 mm Hepes and antibiotics.
Plasmid constructs
Plasmids pSFV-LacZ, 25 pSFV-NP 22 and pSFV-Helper2 26 have been described previously. To create pSFV-P1A, the P1A-encoding cDNA was cloned into pSFV-1 as a BamHI/XmaI fragment. For increased production of P1A, a SFV translational enhancer 52 was fused upstream of amino acid residue 7 of the P1A ORF.
Preparation of rSFV
Recombinant SFV particles were made as previously reported. 26 Briefly, in vitro produced recombinant mRNA was electroporated together with pSFV-Helper2 mRNA into BHK cells. After 24 h viral stocks were harvested and titrated on BHK cells using indirect immunofluorescence staining. 53 Detection of rSFV-expressed proteins Metabolic labeling of BHK-infected cells was done as previously described. 54 Labeled cells were lysed with Nonidet P-40 (NP-40) buffer (1% NP-40/50 mm Tris-HCl, pH 7.4/150 mm NaCl/2 mm EDTA/1 g of phenylmethysulfonyl fluoride (PMSF) per ml) and cleared by centrifugation at 6000 g Immunoprecipitation of cell lysates and immunofluorescence staining of BHK-infected cells was performed as described. 53, 54 For P815 protein detection a rabbit antiserum against P1A was used (kindly provided by Dr Aline Van Pel, Ludwig Institute for Cancer Research, Brussels, Belgium). Cr for 1 h, washed and loaded with peptide (50 m) for 1.5 h at 37°C. After adjusting the appropriate concentration, target cells were mixed with titrated effector CTLs and incubated for 4 h at 37°C in 96-well V-bottomed plates. Supernatants were collected and radioactivity measured in a ␥ counter. Results are expressed as percentage of specific lysis according to the formula: % specific lysis = [( experimental release − spontaneous release)/(maximal release − spontaneous release)] c.p.m. × 100. Peptides used in the assay were synthesized by KJ Ross-Petersen AS, Horsholm, Denmark.
Antibody assay
Detection of antibodies against rSFV expressed antigens was done by ELISA, as described in detail elsewhere. 29 Briefly, BHK cells transfected with rSFV mRNA encoding NP, LacZ or P1A were plated on 96-well dishes. After methanol fixation, sera obtained from immunized mice were added in blocking buffer and incubated overnight at 4°C. After washing with PBS containing 0.05% Tween-20, cells were incubated with alkaline phosphatase conjugated anti-mouse IgG in blocking buffer, substrate PNPP (p-nitrophenyl phosphate) was added and the plates were incubated at room temperature until the absorbance at 405 nm was measured. Serum samples were considered positive only if the OD value of the test sample was twice the absorbance of the LacZ sample. No SFV-P1A or SFV/Enh-P1A immunized mice were found to be seropositive using this method.
Tumor challenge P815 mastocytoma tumor was grown as ascites in DBA/2J mice. Mice vaccinated twice with rSFV were challenged at day 18 after the second rSFV dose by s.c. injection of 10 5 P815 cells into the right flank. Tumors in control mice appeared around day 12. Animals were monitored three times a week. The percent of mice without detectable tumors was assessed by inspection and palpation.
